

**ASX Announcement | 24 June 2020  
Vioneering Technologies (ASX:VTI)**

**Vioneering completes oversubscribed security purchase plan**

**Atlanta, Georgia, USA, 23 June 2020 (24 June 2020 Sydney time)** US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Vioneering Technologies, Inc (ASX: VTI) ('Vioneering' or 'The Company') is pleased to announce the completion of its security purchase plan (SPP).

Under the SPP, eligible holders were offered the opportunity to subscribe up to A\$30,000 of CHES Depository Interests (New CDIs) (representing new fully paid shares of Class A common stock) at an issue price of A\$0.014 per New CDI, together with one free new unlisted option (New Option) for every 2 New CDIs subscribed for. All New CDIs to be issued under the SPP will rank equally in all respect with the existing issued CDIs of Vioneering.

Vioneering sought to raise A\$1 million under the SPP. In accordance with its terms, and due to additional demand from eligible holders, Vioneering increased the size of the SPP. The total amount raised under the SPP was A\$1,067,000 (being 76,214,245 CDIs).

Vioneering will issue the New CDIs and New Options under the SPP to eligible holders on Tuesday, 30 June 2020 in accordance with the timetable set out in the prospectus for the SPP dated 1 June 2020. Holding statements will be dispatched on Wednesday, 1 July 2020.

"Vioneering is very pleased with the support we have received from our existing CDI holders under the SPP" said Vioneering's Chief Executive Officer, Dr Stephen Snowdy. "The funds received under the SPP add to the A\$1.5 million we received under COVID-19 disaster relief in late April and the A\$5.0 million raised in our recent placement in early June. The Company is now funded at its current scale into the third quarter of 2021. Despite downsizing the Company's workforce and enduring the challenges of the ongoing pandemic, Vioneering continues to execute on its growth strategy. We continue to sell our products in the US with our smaller sales force, and expect to generate our first sales in Canada in the near future. We also plan on supporting our partner Menicon's launch in Europe in 2020, and are exploring sales and distribution partnerships to accelerate our growth in Asia. Vioneering thanks the investors that participated in both the placement and the SPP and remains committed to delivering value to our shareholders and quality products to our patients, practitioners, and partners."

**Ends.**

**Authorised for release by Dr Stephen Snowdy, CEO.**

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Julia Maguire The Capital Network M: +61 419 815 386 E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a>

**About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and Visioneering has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

To learn more, please visit: [www.vtvision.com](http://www.vtvision.com)

**Foreign ownership restrictions**

Visioneering’s CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are ‘restricted securities’ under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a ‘FOR US’ designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation,

U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Any forward-looking statements are provided as a guide only and should not be relied upon as an indication or guarantee of future performance. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. You should not place undue reliance on forward-looking statements because they speak only as of the date when made, and are subject to change without notice. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Visioneering does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Visioneering may not actually achieve the plans, projections or expectations disclosed in forward-looking statements.

VTI-IR-ASX-26